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Introduction: In this report, we describe the case of a patient with ocular chemical injury, symblepharon, and
corneal neovascularization in whom subconjunctival injection of bevacizumab caused regression of corneal
opacification and neovascularization, which led to visual improvement.
Case presentation: A 54-year-old Caucasian woman presented at our eye emergency department following a
splash injury of the left eye with sodium hydroxide. At presentation, her visual acuity was light perception. Slit-lamp
examination showed diffuse corneal epithelial defects, stromal edema, and localized Descemet’s folds. Despite
administration of topical and systemic steroids, she developed symblepharon after 3 months as well as superficial
and deep corneal neovascularization with visual acuity 0.5 logarithm of the minimum angle of resolution. A
subconjunctival bevacizumab injection (dose 1.25mg/0.05ml) was administered. After 1 week, the vessels appeared
thinner and corneal opacity was clearer. Her visual acuity improved to 0.3 logarithm of the minimum angle of
resolution. Three weeks later her visual acuity had not changed, and the vessels had started to perfuse again. A
second subconjunctival bevacizumab injection was given. After 2 weeks, her vision had improved to 0.1 logarithm
of the minimum angle of resolution, vessel regression was observed, and corneal opacity was significantly reduced.
Three months after the second injection her vision was unchanged, and the neovascularization remained stable.
During the next months, the patient’s condition was well-controlled, and, at the end of follow-up 24 months later,
her visual acuity and clinical condition were unaltered.
Conclusion: Subconjunctival bevacizumab injection may be considered as a second-line treatment of corneal
neovascularization caused by chemical injury that is unresponsive to conventional steroid therapy.
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Ocular chemical and thermal burns are a devastating
cause of corneal blindness characterized by limbal stem
cell deficiency, stromal opacification, ocular surface ke-
ratinization, corneal and/or conjunctival or ocular sur-
face neovascularization, and high corneal graft failure
rates. Persistent corneal epithelial defects may lead to
tissue thinning or melting, perforation, and secondary
infections. The deepithelialized conjunctival surfaces* Correspondence: l.iannetti@policlinicoumberto1.it
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reproduction in any medium, provided the ortend to fuse and form symblepharon bands. The severity
of the injury depends on the type of offending agent, its
concentration, the duration of exposure, and the extent
of contact [1]. Conventional medical therapies include
steroids, ascorbate, citrates, tetracyclines, lubricants, and
surgical procedures such as the application of a contact
lens and amniotic membrane transplantation [2]. Recently,
the use of subconjunctival bevacizumab, a humanized
monoclonal antibody targeting vascular endothelial
growth factor (VEGF), has been proposed [3-5]. A recent
case report described the use of bevacizumab in a child
with Stevens-Johnson syndrome [3].
We report the case of a patient with ocular chemical
injury, symblepharon, and corneal neovascularization in
whom subconjunctival injection of bevacizumab causedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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zation with resulting visual improvement.
Case presentation
In this report, we describe a retrospective, interventional
case of a 54-year-old Caucasian woman who presented
at our eye emergency department following a splash in-
jury of the left eye with sodium hydroxide. This report
was reviewed and approved by the ethics committee of
the University of Rome “La Sapienza.”
At the first examination, her visual acuity (VA) was
light perception in the left eye. Her eyelids and conjunc-
tiva were congested. A slit-lamp examination showed a
diffuse corneal epithelial defect, stromal edema, and lo-
calized Descemet’s folds. She was treated with 1% dexa-
methasone sodium phosphate drops six times daily, 1%
atropine drops three times daily, and tobramycin six
times daily. The corticosteroid prednisone 50mg was ad-
ministered daily for the first 10 days, then the daily dose
was gradually tapered by 5mg every 15 days. Three
months later, despite the frequent use of topical steroids
a symblepharon with superficial and deep corneal neo-
vascularization was observed (Figure 1). The patient’s
VA was 0.5 logarithm of the minimum angle of reso-
lution (LogMAR). We suggested administering a sub-
conjunctival bevacizumab injection in the left eye with
the aim of reducing corneal neovascularization. Written,
informed consent was obtained from the patient after
explaining the off-label use of bevacizumab on the basis
of two case reports [3,4]. A subconjunctival injection of
0.05ml (1.25mg) of sterile, undiluted, commercially avail-
able bevacizumab (Avastin®; Genentech, South San Francisco,Figure 1 Pre-injection examination revealed symblepharon and
corneal opacity in the inferior sector with superficial and deep
corneal neovascularization (arrows).CA, USA) was administered with topical anesthesia in the
subconjunctival space close to the corneal limbus and ad-
jacent to the pathological blood vessels. After the proced-
ure, the patient was advised to use 0.3% ofloxacin and 1%
dexamethasone sodium phosphate drops three times daily
for one week. One week after the subconjunctival be-
vacizumab injection, the vessels appeared thinner and the
corneal opacity was clearer. The patient’s VA improved to
0.3LogMAR after one week. Three weeks later her VA
had not changed, and the vessels started to perfuse again.
A second subconjunctival bevacizumab injection was then
given. Two weeks after the second injection her VA im-
proved to 0.1LogMAR and corneal neovascularization was
significantly reduced. Notably, three months later her vi-
sion was unchanged and the neovascularization remained
stable (Figure 2). During the next months, the patient’s
condition was well-controlled, and, at the end of follow-
up 24 months later, her VA and clinical condition were
unaltered.
Discussion
The off-label use of bevacizumab in patients with ophthal-
mic diseases involving neovascularization as the primary
or secondary pathology has improved the management of
several diseases, such as age-related macular degeneration,
diabetic retinopathy, corneal neovascularization, neovas-
cular glaucoma, and retinopathy of prematurity. Ocular
surface neovascularization is a prominent feature of ocular
chemical injury that causes visual loss as a result of associ-
ated scarring and lipid deposition. Conventional medicalFigure 2 Examination 3 months after the second injection of
bevacizumab (dose 1.25mg/0.05ml) revealed inferior scarring
and significant reduction of corneal new vessels in number and
size (arrows).
Iannetti et al. Journal of Medical Case Reports 2013, 7:199 Page 3 of 3
http://www.jmedicalcasereports.com/content/7/1/199therapies include steroids, ascorbate, citrates, tetracyclines,
lubricants, and surgical procedures such as application of
a contact lens and amniotic membrane transplantation
[2]. Our data indicate that, when conventional approaches
fail, treatment with subconjunctival bevacizumab may be
effective [3-5]. By giving two subconjunctival bevacizumab
injections, we obtained a dramatic improvement of VA,
and this effect was magnified by the anti-VEGF treatment
that led to a significant reduction of corneal neovascula-
rization. A causal role of the VEGF in promoting ocular
surface neovascularization was thus confirmed [6].Conclusion
To the best of our knowledge, this is one of the first case
reports describing the long-term results of subconjunc-
tival bevacizumab treatment in corneal neovascularization
secondary to ocular chemical injury. Subconjunctival
bevacizumab injection may be considered as an optional
treatment in patients who do not respond to conventional
steroid therapy. Future studies will explore this therapy to-
ward a feasible standardization.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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